Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Bacterial-Based Methods for Cancer Treatment: What We Know and Where We Are

Bacterial-Based Methods for Cancer Treatment: What We Know and Where We Are A severe disease, cancer is caused by the exponential and uncontrolled growth of cells, leading to organ dysfunction as well as disorders. This disease has been recognized as one of the significant challenges to health and medicine. Various treatment procedures for cancer are associated with diverse side effects; the most conventional cancer treatments include chemotherapy, surgery, and radiotherapy, among others. Numerous adverse and side effects, low specificity and sensitivity, narrow therapeutic windows, and, recently, the emergence of tumor cells resistant to such treatments have been documented as the shortcomings of conventional treatment strategies. As a group of prokaryotic microorganisms, bacteria have great potential for use in cancer therapy. Currently, utilizing bacteria for cancer treatment has attracted the attention of scientists. The high potential of bacteria to become non-pathogenic by genetic manipulation, their distinguished virulence factors (which can be used as weapons against tumors), their ability to proliferate in tissues, and the contingency to control their population by administrating antibiotics, etc., have made bacteria viable candidates and live micro-medication for cancer therapies. However, the possible cytotoxicity impacts of bacteria, their inability to entirely lyse cancerous cells, as well as the probability of mutations in their genomes are among the significant challenges of bacteria-based methods for cancer treatment. In this article, various available data on bacterial therapeutics, along with their pros and cons, are discussed. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Bacterial-Based Methods for Cancer Treatment: What We Know and Where We Are

Rommasi, Foad
Oncology and Therapy , Volume 10 (1) – Jun 1, 2022
Download PDF
32 pages

Loading next page...
 
/lp/springer-journals/bacterial-based-methods-for-cancer-treatment-what-we-know-and-where-we-Jc0n8pfAe5
Publisher
Springer Journals
Copyright
Copyright © The Author(s) 2021
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-021-00177-x
Publisher site
See Article on Publisher Site

Abstract

A severe disease, cancer is caused by the exponential and uncontrolled growth of cells, leading to organ dysfunction as well as disorders. This disease has been recognized as one of the significant challenges to health and medicine. Various treatment procedures for cancer are associated with diverse side effects; the most conventional cancer treatments include chemotherapy, surgery, and radiotherapy, among others. Numerous adverse and side effects, low specificity and sensitivity, narrow therapeutic windows, and, recently, the emergence of tumor cells resistant to such treatments have been documented as the shortcomings of conventional treatment strategies. As a group of prokaryotic microorganisms, bacteria have great potential for use in cancer therapy. Currently, utilizing bacteria for cancer treatment has attracted the attention of scientists. The high potential of bacteria to become non-pathogenic by genetic manipulation, their distinguished virulence factors (which can be used as weapons against tumors), their ability to proliferate in tissues, and the contingency to control their population by administrating antibiotics, etc., have made bacteria viable candidates and live micro-medication for cancer therapies. However, the possible cytotoxicity impacts of bacteria, their inability to entirely lyse cancerous cells, as well as the probability of mutations in their genomes are among the significant challenges of bacteria-based methods for cancer treatment. In this article, various available data on bacterial therapeutics, along with their pros and cons, are discussed.

Journal

Oncology and Therapy – Springer Journals

Published: Jun 1, 2022

Keywords: Bacterial therapeutics; Bacteriotherapy; Cancer treatment; Immunotherapy; Microbial metabolites; Multimodal therapies

References

  • Tumor cell morphology
    Baba, AI; Câtoi, C
  • New approaches for the treatment of cancer
    Jain, R
  • Innovative approaches for cancer treatment: current perspectives and new challenges
    Pucci, C; Martinelli, C; Ciofani, G
  • Complementary and alternative therapies for cancer
    Cassileth, BR; Deng, G
  • Cancer treatment and survivorship statistics, 2016
    Miller, KD; Siegel, RL; Lin, CC; Mariotto, AB; Kramer, JL; Rowland, JH
  • Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses
    Roberts, NJ; Zhang, L; Janku, F; Collins, A; Bai, R-Y; Staedtke, V
  • Localization of the vegetative form of Clostridium tetani in mouse tumors following intravenous spore administration
    Malmgren, RA; Flanigan, CC
  • Intratumoral injection of clostridium novyi-nt spores in patients with treatment-refractory advanced solid tumors
    Janku, F; Zhang, HH; Pezeshki, A; Goel, S; Murthy, R; Wang-Gillam, A
  • Bacteria as tumor therapeutics?
    Oelschlaeger, TA
  • Aus der Sitzung der medicinischen section vom 13 November 1867
    Busch, W
  • Ueber die züchtung der erysipelkokken auf künstlichem nährboden und ihre übertragbarkeit auf den menschen
    Fehleisen, F
  • Disappearance of a recurrent carcinoma after injections of mixed toxins
    Coley, W
  • Immunology of tuberculosis
    Flynn, JL; Chan, J
  • History of tuberculosis
    Daniel, TM; Bates, JH; Downes, KA
  • Organization WH BCG vaccines: WHO position paper–February 2018–Vaccins BCG: note de synthèse de l’OMS–Février 20188
  • History of BCG vaccine
    Simona, L; Mihaescu, T
  • In vitro culture medium influences the vaccine efficacy of Mycobacterium bovis BCG
    Venkataswamy, MM; Goldberg, MF; Baena, A; Chan, J; Jacobs, WR; Porcelli, SA
  • Protective efficacy of a DNA vaccine encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcer
    Tanghe, A; Content, J; Van Vooren, J-P; Portaels, F; Huygen, K
  • Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy
    Rentsch, CA; Birkhäuser, FD; Biot, C; Gsponer, JR; Bisiaux, A; Wetterauer, C
  • The role of bacillus Calmette-Guérin in the treatment of non–muscle-invasive bladder cancer
    Gontero, P; Bohle, A; Malmstrom, P-U; O’Donnell, MA; Oderda, M; Sylvester, R
  • The use of intravesical BCG in urothelial carcinoma of the bladder
    Alhunaidi, O; Zlotta, AR
  • Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect
    Han, J; Gu, X; Li, Y; Wu, Q
  • Bacille Calmette-Guerin can induce cellular apoptosis of urothelial cancer directly through toll-like receptor 7 activation
    Yu, D-S; Wu, C-L; Ping, S-Y; Keng, C; Shen, K-H
  • Mycobacterium bovis Bacillus Calmette-Guerin and its cell wall complex induce a novel lysosomal membrane protein, SIMPLE, that bridges the missing link between lipopolysaccharide and p53-inducible gene, LITAF (PIG7), and estrogen-inducible gene, EET-1
    Moriwaki, Y; Begum, NA; Kobayashi, M; Matsumoto, M; Toyoshima, K; Seya, T
  • Genetic control of the innate immune response
    Wells, CA; Ravasi, T; Faulkner, GJ; Carninci, P; Okazaki, Y; Hayashizaki, Y
  • TLR4-and TLR9-dependent effects on cytokines, cell viability, and invasion in human bladder cancer cells
    Olbert, PJ; Kesch, C; Henrici, M; Subtil, FS; Honacker, A; Hegele, A
  • Autocrine IL-6 production by human transitional carcinoma cells upregulates expression of the α5β1 fibronectin receptor
    Zhang, G-J; Crist, SA; Mckerrow, AK; Xu, Y; Ladehoff, DC; See, WA
  • Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement
    Brandau, S; Suttmann, H
  • Prognostic value of Bcl-2 and Bax tumor cell expression in patients with non muscle-invasive bladder cancer receiving bacillus Calmette-Guerin immunotherapy
    Ajili, F; Kaabi, B; Darouiche, A; Tounsi, H; Kourda, N; Chebil, M
  • Live bacteria as anticancer agents and tumor-selective protein delivery vectors
    Bermudes, D; Zheng, L; King, IC
  • Recombinant Listeria promotes tumor rejection by CD8+ T cell-dependent remodeling of the tumor microenvironment
    Deng, W; Lira, V; Hudson, TE; Lemmens, EE; Hanson, WG; Flores, R
  • Shigella mediated depletion of macrophages in a murine breast cancer model is associated with tumor regression
    Galmbacher, K; Heisig, M; Hotz, C; Wischhusen, J; Galmiche, A; Bergmann, B
  • Systems metabolic engineering of Escherichia coli for production of the antitumor drugs violacein and deoxyviolacein
    Rodrigues, AL; Trachtmann, N; Becker, J; Lohanatha, AF; Blotenberg, J; Bolten, CJ
  • When bacteria become mutagenic and carcinogenic: lessons from H. pylori
    Touati, E
  • Innate and adaptive immune cells in the tumor microenvironment
    Gajewski, TF; Schreiber, H; Fu, Y-X
  • Cytotoxic CD8+ T cells in cancer and cancer immunotherapy
    Raskov, H; Orhan, A; Christensen, JP; Gögenur, I
  • Induction of CD 4+ and CD 8+ antitumor effector T cell responses by bacteria mediated tumor therapy
    Stern, C; Kasnitz, N; Kocijancic, D; Trittel, S; Riese, P; Guzman, CA
  • In tumors Salmonella migrate away from vasculature toward the transition zone and induce apoptosis
    Ganai, S; Arenas, RB; Sauer, JP; Bentley, B; Forbes, NS
  • The role of bacteria in cancer therapy–enemies in the past, but allies at present
    Song, S; Vuai, MS; Zhong, M
  • Bacteria and genetically modified bacteria as cancer therapeutics: current advances and challenges
    Nallar, SC; Xu, D-Q; Kalvakolanu, DV
  • Continuous intravenous administration of live genetically modified salmonella typhimurium in patients with metastatic melanoma
    Heimann, DM; Rosenberg, SA
  • Therapeutic bacteria to combat cancer; current advances, challenges, and opportunities
    Sedighi, M; Zahedi Bialvaei, A; Hamblin, MR; Ohadi, E; Asadi, A; Halajzadeh, M
  • Bacteria and bacterial anticancer agents as a promising alternative for cancer therapeutics
    Baindara, P; Mandal, SM
  • Cellular constituents of immune escape within the tumor microenvironment
    Kerkar, SP; Restifo, NP
  • Tumor associated macrophages and neutrophils in cancer
    Galdiero, MR; Bonavita, E; Barajon, I; Garlanda, C; Mantovani, A; Jaillon, S
  • Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses
    Rodriguez, PC; Quiceno, DG; Zabaleta, J; Ortiz, B; Zea, AH; Piazuelo, MB
  • The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC
    Fabian, MR; Sonenberg, N
  • Macrophage activation and polarization
    Martinez, F; Sica, A; Mantovani, A; Locati, M
  • Management of adverse events related to new cancer immunotherapy (immune checkpoint inhibitors)
    Bourke, JM; O’Sullivan, M; Khattak, MA
  • Cancer immunotherapy—immune checkpoint blockade and associated endocrinopathies
    Byun, DJ; Wolchok, JD; Rosenberg, LM; Girotra, M
  • The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis
    Gu, L; Khadaroo, PA; Su, H; Kong, L; Chen, L; Wang, X
  • CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients
    Ott, PA; Hodi, FS; Robert, C
  • Pd-1/pd-l1 inhibitors
    Sunshine, J; Taube, JM
  • Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma
    McDermott, D; Lebbé, C; Hodi, FS; Maio, M; Weber, JS; Wolchok, JD
  • The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas
    McCarthy, EF
  • Live-attenuated bacteria as a cancer vaccine vector
    Toussaint, B; Chauchet, X; Wang, Y; Polack, B; Gouëllec, AL
  • BCG vaccines: their mechanisms of attenuation and impact on safety and protective efficacy
    Liu, J; Tran, V; Leung, AS; Alexander, DC; Zhu, B
  • Pertussis: challenges today and for the future
    Cherry, JD
  • Pertussis vaccines
    Edwards, KM; Decker, MD
  • Bacterial vectors and delivery systems in cancer therapy
    Gardlik, R; Fruehauf, JH
  • New paradigm for tumor theranostic methodology using bacteria-based microrobot
    Park, SJ; Park, S-H; Cho, S; Kim, D-M; Lee, Y; Ko, SY
  • Effect of chitosan coating on a bacteria-based alginate microrobot
    Park, SJ; Lee, YK; Cho, S; Uthaman, S; Park, IK; Min, JJ
  • Novel selective detection method of tumor angiogenesis factors using living nano-robots
    Al-Fandi, M; Alshraiedeh, N; Oweis, R; Alshdaifat, H; Al-Mahaseneh, O; Al-Tall, K
  • Microbiota and cancer immunotherapy: in search of microbial signals
    Gharaibeh, RZ; Jobin, C
  • Role of listeriolysin O in cell-to-cell spread of listeria monocytogenes
    Gedde, MM; Higgins, DE; Tilney, LG; Portnoy, DA
  • Pharmacologic and toxicologic evaluation of C. novyi-NT spores
    Diaz, LA; Cheong, I; Foss, CA; Zhang, X; Peters, BA; Agrawal, N
  • ROS-modulated therapeutic approaches in cancer treatment
    Raza, MH; Siraj, S; Arshad, A; Waheed, U; Aldakheel, F; Alduraywish, S
  • Explicit hypoxia targeting with tumor suppression by creating an “obligate” anaerobic Salmonella Typhimurium strain
    Yu, B; Yang, M; Shi, L; Yao, Y; Jiang, Q; Li, X
  • Salmonella-induced caspase-2 activation in macrophages: a novel mechanism in pathogen-mediated apoptosis
    Jesenberger, V; Procyk, KJ; Yuan, J; Reipert, S; Baccarini, M
  • Targeted cancer therapy using engineered Salmonella typhimurium
    Zheng, JH; Min, J-J
  • Strains, mechanism, and perspective: Salmonella-based cancer therapy
    Wang, C-Z; Kazmierczak, RA; Eisenstark, A
  • The listeriolysin O gene: a chromosomal locus crucial for the virulence of Listeria monocytogenes
    Cossart, P
  • Listeria monocytogenes virulence factors, including listeriolysin O, are secreted in biologically active extracellular vesicles
    Coelho, C; Brown, L; Maryam, M; Vij, R; Smith, DF; Burnet, MC
  • Listeria monocytogenes as a vector for cancer immunotherapy: current understanding and progress
    Flickinger, JC; Rodeck, U; Snook, AE
  • Attenuated Listeria monocytogenes as a cancer vaccine vector for the delivery of CD24, a biomarker for hepatic cancer stem cells
    Yang, Y; Hou, J; Lin, Z; Zhuo, H; Chen, D; Zhang, X
  • Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse
    Singh, R; Dominiecki, ME; Jaffee, EM; Paterson, Y
  • Antitumor mechanisms of bifidobacteria
    Wei, H; Chen, L; Lian, G; Yang, J; Li, F; Zou, Y
  • Anti-proliferative effects of Bifidobacterium adolescentis SPM0212 extract on human colon cancer cell lines
    Lee, DK; Jang, S; Kim, MJ; Kim, JH; Chung, MJ; Kim, KJ
  • Clostridial spores for cancer therapy: targeting solid tumour microenvironment
    Umer, B; Good, D; Anné, J; Duan, W; Wei, MQ
  • Methods for the development of tumor-targeting bacteria
    Hoffman, RM; Zhao, M
  • Learning from clostridium novyi-NT: how to defeat cancer
    Wang, L; Wang, Q; Tian, X; Shi, X
  • A novel lactic acid bacteria mixture: macrophage-targeted prophylactic intervention in colorectal cancer management
    Hradicka, P; Beal, J; Kassayova, M; Foey, A; Demeckova, V
  • Programmable probiotics for detection of cancer in urine
    Danino, T; Prindle, A; Kwong, GA; Skalak, M; Li, H; Allen, K
  • Programmable bacteria induce durable tumor regression and systemic antitumor immunity
    Chowdhury, S; Castro, S; Coker, C; Hinchliffe, TE; Arpaia, N; Danino, T
  • Bacterial virulence factors: secreted for survival
    Sharma, AK; Dhasmana, N; Dubey, N; Kumar, N; Gangwal, A; Gupta, M
  • The role of plant-derived natural substances as immunomodulatory agents in carcinogenesis
    Samec, M; Liskova, A; Koklesova, L; Samuel, SM; Murin, R; Zubor, P
  • MAPK signaling pathway-targeted marine compounds in cancer therapy
    Wei, J; Liu, R; Hu, X; Liang, T; Zhou, Z; Huang, Z
  • Arenamides A−C, cytotoxic NFκB inhibitors from the marine actinomycete Salinispora arenicola
    Asolkar, RN; Freel, KC; Jensen, PR; Fenical, W; Kondratyuk, TP; Park, E-J
  • Arenimycin, an antibiotic effective against rifampin-and methicillin-resistant Staphylococcus aureus from the marine actinomycete Salinispora arenicola
    Asolkar, RN; Kirkland, TN; Jensen, PR; Fenical, W
  • Antifungal cyclopeptides from Halobacillus litoralis YS3106 of marine origin
    Yang, L; Tan, R-x; Wang, Q; Huang, W-y; Yin, Y-x
  • Anticancer activity of bacterial proteins and peptides
    Karpiński, TM; Adamczak, A
  • Ieodoglucomides A and B from a marine-derived bacterium Bacillus licheniformis
    Tareq, FS; Kim, JH; Lee, MA; Lee, H-S; Lee, Y-J; Lee, JS
  • Antitumor compounds from marine actinomycetes
    Olano, C; Méndez, C; Salas, JA
  • Lucentamycins A−D, cytotoxic peptides from the marine-derived actinomycete Nocardiopsis lucentensis
    Cho, JY; Williams, PG; Kwon, HC; Jensen, PR; Fenical, W
  • Bacteriotherapy in gastrointestinal cancer
    Soleimanpour, S; Hasanian, SM; Avan, A; Yaghoubi, A; Khazaei, M
  • Effect of Helicobacter pylori infection on expressions of Bcl-2 family members in gastric adenocarcinoma
    Zhang, H; Fang, D-C; Wang, R-Q; Yang, S-M; Liu, H-F; Luo, Y-H
  • Diversity of secondary metabolites from marine Bacillus species: chemistry and biological activity
    Mondol, MAM; Shin, HJ; Islam, MT
  • Microbial amphiphiles: a class of promising new-generation anticancer agents
    Dey, G; Bharti, R; Sen, R; Mandal, M
  • Urukthapelstatin A, a novel cytotoxic substance from marine-derived Mechercharimyces asporophorigenens YM11-542
    Matsuo, Y; Kanoh, K; Yamori, T; Kasai, H; Katsuta, A; Adachi, K
  • Biomimetic synthesis of urukthapelstatin A by Aza-Wittig ring contraction
    Schwenk, S; Ronco, C; Oberheide, A; Arndt, HD
  • Anticancer peptides from bacteria
    Karpiński, TM; Szkaradkiewicz, AK
  • Functional and structural characteristics of anticancer peptide Pep27 analogues
    Lee, DG; Hahm, K-S; Park, Y; Kim, H-Y; Lee, W; Lim, S-C
  • Bacterial proteinaceous compounds with multiple activities toward cancers and microbial infection
    Rodrigues, G; Silva, GGO; Buccini, DF; Duque, HM; Dias, SC; Franco, OL
  • Synergistic effect of the pro-apoptosis peptide kla-TAT and the cationic anticancer peptide HPRP-A1
    Hu, C; Chen, X; Huang, Y; Chen, Y
  • Peptides with dual antimicrobial-anticancer activity derived from the N-terminal region of H pylori ribosomal protein L1 (RpL1)
    Yaghoubi, A; Khazaei, M; Ghazvini, K; Movaqar, A; Avan, A; Hasanian, SM
  • Lantibiotics, class I bacteriocins from the genus Bacillus
    Lee, HJ; Kim, HY
  • The circular bacteriocins gassericin A and circularin A
    Kawai, Y; Kemperman, R; Kok, J; Saito, T
  • Population attributable risk of invasive postmenopausal breast cancer and breast cancer subtypes for modifiable and non-modifiable risk factors
    Barnes, BB; Steindorf, K; Hein, R; Flesch-Janys, D; Chang-Claude, J
  • Toxicity of bovicin HC5 against mammalian cell lines and the role of cholesterol in bacteriocin activity
    Paiva, AD; de Oliveira, MD; de Paula, SO; Baracat-Pereira, MC; Breukink, E; Mantovani, HC
  • Interaction with lipid II induces conformational changes in bovicin HC5 structure
    Paiva, AD; Irving, N; Breukink, E; Mantovani, HC
  • In vitro characterization and evaluation of the cytotoxicity effects of nisin and nisin-loaded PLA-PEG-PLA nanoparticles on gastrointestinal (AGS and KYSE-30), hepatic (HepG2) and blood (K562) cancer cell lines
    Goudarzi, F; Asadi, A; Afsharpour, M; Jamadi, RH
  • Nisin induces cytotoxicity and apoptosis in human asterocytoma cell line (SW1088)
    Zainodini, N; Hassanshahi, G; Hajizadeh, M; Falahati-Pour, SK; Mahmoodi, M; Mirzaei, MR
  • Nisin, a potent bacteriocin and anti-bacterial peptide, attenuates expression of metastatic genes in colorectal cancer cell lines
    Norouzi, Z; Salimi, A; Halabian, R; Fahimi, H
  • Increased expression of caspase genes in colorectal cancer cell line by nisin
    Hosseini, SS; Hajikhani, B; Faghihloo, E; Goudarzi, H
  • Purification, characterization and in vitro cytotoxicity of the bacteriocin from Pediococcus acidilactici K2a2-3 against human colon adenocarcinoma (HT29) and human cervical carcinoma (HeLa) cells
    Villarante, KI; Elegado, FB; Iwatani, S; Zendo, T; Sonomoto, K; de Guzman, EE
  • Pediocins
    Ray, B; Hoover, DG
  • Isolation and In vitro characterization of anti-Gardnerella vaginalis bacteriocin producing Lactobacillus fermentum HV6b isolated from human vaginal ecosystem
    Kaur, B; Balgir, P; Mittu, B; Chauhan, A; Kumar, B; Garg, N
  • Biomedical applications of fermenticin HV6b isolated from Lactobacillus fermentum HV6b MTCC10770
    Kaur, B; Balgir, PP; Mittu, B; Kumar, B; Garg, N
  • The cytotoxic and cytocidal effect of colicin E3 on mammalian tissue cells
    Šmarda, J; Obdržálek, V; Táborský, I; Mach, J
  • Pore-forming toxins
    Gilbert, R
  • Bacteriocins as potential anticancer agents
    Kaur, S; Kaur, S
  • Molecular structures and functions of pyocins S1 and S2 in Pseudomonas aeruginosa
    Sano, Y; Matsui, H; Kobayashi, M; Kageyama, M
  • Cytotoxicity of pyocin S2 to tumor and normal cells and its interaction with cell surfaces
    Watanabe, T; Saito, H
  • Cytotoxic effects of pyocin S2 produced by Pseudomonas aeruginosa on the growth of three human cell lines
    Abdi-Ali, A; Worobec, E; Deezagi, A; Malekzadeh, F
  • Mechanism of diphtheria toxin catalytic domain delivery to the eukaryotic cell cytosol and the cellular factors that directly participate in the process
    Murphy, JR
  • Inhibition of adrenocortical carcinoma by diphtheria toxin mutant CRM197
    Martarelli, D; Pompei, P; Mazzoni, G
  • Primary cutaneous anaplastic large-cell lymphoma: complete remission for 13 years after denileukin diftitox
    Lewis, DJ; Dao, H; Nagarajan, P; Duvic, M
  • Clostridium difficile toxins: mechanism of action and role in disease
    Voth, DE; Ballard, JD
  • Clostridium difficile toxin B recombinant protein inhibits tumor growth and induces apoptosis through inhibiting Bcl-2 expression, triggering inflammatory responses and activating C-erbB-2 and Cox-2 expression in breast cancer mouse model
    Zhang, Y; Li, Y; Li, H; Chen, W; Liu, W
  • Bacterial toxins and their carbohydrate receptors at the host–pathogen interface
    Lingwood, CA; Mahfoud, R
  • Escherichia coli verotoxin 1 mediates apoptosis in human HCT116 colon cancer cells by inducing overexpression of the GADD family of genes and S phase arrest
    Bhattacharjee, RN; Park, K-S; Uematsu, S; Okada, K; Hoshino, K; Takeda, K
  • Poly (ethylene glycol)(PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties
    Holtsberg, FW; Ensor, CM; Steiner, MR; Bomalaski, JS; Clark, MA
  • Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis
    Kim, RH; Coates, JM; Bowles, TL; McNerney, GP; Sutcliffe, J; Jung, JU
  • Bacteria as vectors for gene therapy of cancer
    Baban, CK; Cronin, M; O’Hanlon, D; O’Sullivan, GC; Tangney, M
  • Gene therapy for cancer: present status and future perspective
    Amer, MH
  • Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors
    Morales, A; Eidinger, D; Bruce, A
  • BCG immunotherapy of bladder cancer: 20 years on
    Alexandroff, AB; Jackson, AM; O’Donnell, MA; James, K
  • The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix
    Maciag, PC; Radulovic, S; Rothman, J
  • A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction
    Le, DT; Brockstedt, DG; Nir-Paz, R; Hampl, J; Mathur, S; Nemunaitis, J
  • Cancer immunotherapy using Listeria monocytogenes and listerial virulence factors
    Wood, LM; Guirnalda, PD; Seavey, MM; Paterson, Y
  • Anaerobic bacteria as a gene delivery system for breast cancer therapy. Nihon rinsho
    Fujimori, M
  • Genetically engineered Bifidobacterium as a drug delivery system for systemic therapy of metastatic breast cancer patients
    Fujimori, M
  • Genetically engineered Bifidobacterium longum for tumor-targeting enzyme-prodrug therapy of autochthonous mammary tumors in rats
    Sasaki, T; Fujimori, M; Hamaji, Y; Hama, Y; Ki, I; Amano, J
  • Bacterial vectors for imaging and cancer gene therapy: a review
    Cronin, M; Stanton, R; Francis, K; Tangney, M
  • Tumor-activated prodrugs—a new approach to cancer therapy
    Denny, WA
  • Designed antimicrobial and antitumor peptides with high selectivity
    Hu, J; Chen, C; Zhang, S; Zhao, X; Xu, H; Zhao, X
  • Improved anticancer potency by head-to-tail cyclization of short cationic anticancer peptides containing a lipophilic β2, 2-amino acid
    Tørfoss, V; Isaksson, J; Ausbacher, D; Brandsdal, BO; Flaten, GE; Anderssen, T
  • Combination bacteriolytic therapy for the treatment of experimental tumors
    Dang, LH; Bettegowda, C; Huso, DL; Kinzler, KW; Vogelstein, B
  • Perspectives in vector development for systemic cancer gene therapy
    Hatefi, A; Canine, BF
  • Bacteria in cancer therapy: a novel experimental strategy
    Patyar, S; Joshi, R; Byrav, DP; Prakash, A; Medhi, B; Das, B